ST
AXDX

Spot Trading’s Accelerate Diagnostics AXDX Stock Holding History

Spot Trading’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-1,000
Closed -$260K – 4298
2014
Q2 		$260K Buy
+1,000
New +$218K ﹤0.01% 3152

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WIC
Wood Investment Counsel Denver, Colorado $669M AUM 20.44% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
MGM
Miura Global Management New York $43.8M AUM 53.8% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SM
Selkirk Management Chatham, New Jersey $294M AUM 26.84% 1-Year Est. Return

Spot Trading's AXDX Position: Q3 2014 in Review

Spot Trading sold out of Accelerate Diagnostics (AXDX) in Q3 2014, closing a stake of 20 shares — an estimated $5K sold.

Spot Trading first reported a position in AXDX in Q2 2014 and held it in 1 quarter. The position peaked at $5K in Q2 2014. 71 funds tracked by Wall St. Rank hold AXDX as of Q3 2014.

  • Spot Trading reported no remaining Accelerate Diagnostics position as of Q3 2014 after selling out during the quarter.
  • Spot Trading sold 20 Accelerate Diagnostics shares in Q3 2014, an estimated $5K.
  • Spot Trading first reported a position in Accelerate Diagnostics in Q2 2014 and held it in 1 quarter.
  • Spot Trading's Accelerate Diagnostics position peaked at $5K in Q2 2014.
  • 71 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2014.

Based on Spot Trading's 13F filing for Q3 2014, filed 13 Nov 2014.